By determining the -lactam susceptibility of Enterobacteriaceae isolated in Eastern Romania from 1985 to 1993, three Escherichia coli, three Salmonella typhimurium and one Klebsiella pneumoniae isolates with reduced susceptibility to co-amoxiclav were found. The antibiotic susceptibility of the isolates and their E. coli derivatives, and kinetic values suggested the following resistance mechanisms: hyperproduction of TEM in S. typhimurium, limited antibiotic uptake in K. pneumoniae and OXA production in one strain of E. coli. Despite a normal -lactamase activity, the two remaining E. coli strains and their derivatives were less susceptible to co-amoxiclav.
Introduction
-Lactamase production is the most important mechanism of bacterial resistance to -lactam antibiotics. To overcome penicillinase production, -lactam antibiotics which are not hydrolysed by these enzymes, and -lactamase inhibitors (clavulanate, sulbactam or tazobactam) have been developed. In Western European countries, coamoxiclav was introduced around [1985] [1986] . As early as 1987, amoxycillin-resistant isolates of Escherichia coli less susceptible to co-amoxiclav were described. 1 Four mechanisms of E. coli resistance to co-amoxiclav have now been reported: hyperproduction of TEM -lactamases, 2 modification of the outer membrane protein limiting the uptake of the antibiotic combination, 3 production of OXA-type enzymes 4, 5 and production of IRT -lactamases derived from the -lactamase TEM-1 by various amino acid substitutions. 4, 6 Co-amoxiclav has been used in Romania since 1990. The microbiology laboratory of the University of I a s i , serving as reference centre for Eastern Romania, determined the -lactam resistance of approximately 1500 Enterobacteriaceae which were collected by seven regional laboratories from 1985 to 1993. Seven isolates belonging to species normally susceptible to co-amoxiclav (E. coli, Salmonella spp. and Klebsiella spp.) were found with reduced susceptibility. The present study was undertaken to gain more insight into the mechanisms involved in the co-amoxiclav resistance of these strains.
Materials and methods

Bacterial strains
Seven clinical isolates of Enterobacteriaceae with reduced susceptibility to co-amoxiclav were analysed. These were one K. pneumoniae (strain 40) isolated from the urine of a patient hospitalized in the gynaecology hospital of Iasi in 1991, three E. coli strains (E. coli P isolated from the urine of a patient hospitalized in Iasi in 1990, and E. coli 912 and E. coli 177 isolated in 1989 and 1993, respectively, from stools of healthy carriers of Iasi and Vaski) and three S. typhimurium strains (76, 77 and 78) isolated from stools of healthy carriers, with two in 1987 in Iasi and one in 1985 in Vrancea. E. coli J53-2 resistant to rifampicin was used in the mating experiments.
The species were identified using the API 20E system (bioMérieux, Marcy l'Etoile, France) and the serovar of Salmonella by using a slide agglutination method (Sanofi Diagnostic Pasteur, Marne la Coquette, France) 
Reduced susceptibility to co-amoxiclav in
Susceptibility testing
The susceptibility to 18 antibiotics was determined by the disc agar diffusion method using Mueller-Hinton medium (bioMérieux, France). MICs of amoxycillin and clavulanic acid (SmithKline Beecham, Paris, France), alone or combined in a ratio 2 : 1 were measured by a two-fold agar dilution method with an inoculum of 10 4 cfu per spot. Zone inhibition diameters and MICs were interpreted according to the recommendations of the Antibiogram Committee of the French Microbiology Society. 7 
Plasmid transfer
Plasmid-mediated resistance was transferred by conj u g ation as previously described. 8 The transconjugants w e r e selected on agar containing ampicillin 150 mg/L and rifampicin 100 mg/L.
-Lactamase isoelectrofocusing and activity
Isoelectric focusing was performed in comparison with standard enzymes with the following pI values: TEM-1: 5.4; TEM-2: 5.6; TEM-101: 5.15; SHV-3: 7; SHV-4: 7.8. The -lactamase activity and the inhibitory action of clavulanic acid were determined, as previously reported 5 on the crude extracts of the clinical isolates, the K. pneumoniae 40-derived E. coli and two E. coli strains producing native TEM-1 and IRT-3, respectively.
Results and discussion
The seven clinical isolates and their respective E. coli derivatives were resistant to amoxycillin and ticarcillin, suggesting the presence of transferable plasmid-encoded -lactamases (Table I) . Escherichia coli derivatives also showed reduced susceptibility to co-amoxiclav (MIC 4/2 mg/L) but with a MIC which was generally lower than that observed with the donor clinical isolates, especially for the K. pneumoniae 40-derived E. coli which was even susceptible to co-amoxiclav by the disc agar diffusion method (Table I ). The further resistance markers that were transferred from the three S. typhimurium strains were identical (gentamicin, kanamycin, tetracycline, chloramphenicol, sulphamethoxazole and trimethoprim) while those transferred from the three E. coli clinical isolates were different: tetracycline from E. coli P, gentamicin, sulphamethoxazole and trimethoprim from E. coli 912, and chloramphenicol from E. coli 177 (Table I) . Another pattern of resistance (kanamycin, chloramphenicol and trimethoprim) was transferred from the K. pneumoniae strain 40 (Table I ). The different transferable resistance patterns allow the possibility of the same plasmid spreading into different species to be excluded, but in the case of the identical resistance pattern of the salmonella isolates, clonal relatedness of these strains, especially of the two isolated in 1987 in Iasi, cannot be excluded.
All the S. typhimurium isolates and two E. coli isolates (P and 912) produced a -lactamase with a pI of 5.4 co-migrating with TEM-1 while E. coli 177 produced an enzyme of pI 7.7 which was able to hydrolyse oxacillin (Table II) . The K. pneumoniae strain 40 exhibited two penicillin G hydrolysing enzymes, one of pI 7.7 corresponding to the chromosomally encoded -lactamase and one of pI 5.4 co-migrating with TEM-1. In order to evaluate the activity of the transferable -lactamase produced by the K. pneumoniae strain 40, the kinetic tests were also applied on its E. coli derivative. In this case, the enzyme of pI 5.4 had a low -lactamase activity similar to that of the -lactamase IRT-3 but showed a K m value for pencillin G similar to that of the native TEM-1 (Table II) . In contrast, the -lactamase activity displayed by the TEM-1 co-migrating enzymes of the other clinical isolates was similar to or higher than that of the native TEM-1 (Table  II) .
The residual -lactamase activity measured in the presence of clavulanic acid was 9% with native TEM-1 and 76% with IRT-3. Except OXA-1 (E. coli 177) which appeared highly unstable in these experimental conditions, the transferable TEM-1 co-migrating -l a c t a m a s e s of the clinical isolates showed a residual activity of 10%, like the native TEM-1 (Table II) .
These results showed that only two types of transferable -lactamases, OXA-1 and TEM-1, were involved in the reduction of the susceptibility to co-amoxiclav of the seven strains isolated before (n 5) and after ( n 2) the therapeutic use of this combination in Romania. Escherichia coli 177 producing OXA-1 was isolated from stools of a healthy carrier in 1993. Interestingly, such E. coli strains were described at the same time in Western European countries 4, 5 where co-amoxiclav was introduced much earlier.
Regarding the MICs of co-amoxiclav against their respective derivatives, the reduced susceptibility of E. coli P and 912 seems to be strictly related to the transferable -lactamase co-migrating with TEM-1. Nevertheless, the hyperproduction previously described by Martinez 2 can be excluded by -lactamase activity values (Table II) . Inversely, the higher level of the -lactamase activity displayed by the three S. typhimurium strains suggests the hyperproduction of the TEM-1 -lactamase, which has not yet been reported in this species.
Despite a transferable -lactamase with an activity surprisingly ten-fold lower than that of the native TEM-1, the K. pneumoniae strain, but not its derivative, was resistant to co-amoxiclav. The resistance of the K. pneumoniae strain to cefoxitin and quinolones, suggested decreased permeability as already reported in co-amoxiclav-resistant E. coli 3 and extended-spectrum -lactamase-producing K. pneumoniae. 9 In conclusion, this study suggests that the same m e c h a-nisms responsible for the reduced co-amoxiclav susceptibility in E. coli can be found in other enterobacterial species such as Salmonella and Klebsiella, and, moreover, in strains isolated both before and after the introduction of co-amoxiclav. In addition, we found that normally produced TEM-1 -lactamase can be involved in reduced susceptibility to co-amoxiclav in E. coli. Further studies are necessary to understand this finding. 
